A new study reports that Radiesse, the calcium hydroxylapatite-based injectable, boosts collagen production and additional key extracellular matrix (ECM) proteins while improving visible signs of solar elastosis. The Dermatology Digest covered the findings, which position the filler as more than a volumizing agent.

Radiesse's mechanism has long been described as biostimulatory: the carrier gel provides immediate correction, while calcium hydroxylapatite microspheres are thought to trigger a fibroblast response that generates new collagen. What sets this study apart is its documentation of changes beyond collagen alone.

Which proteins moved?

The researchers measured not just collagen but a broader set of ECM proteins — the structural network that includes elastin-related components and supporting matrix molecules degraded by chronic sun exposure. Solar elastosis, the hallmark of cumulative UV damage, shows up histologically as amorphous elastotic material replacing normal dermal architecture. According to the study, treatment with Radiesse improved the clinical signs of that degeneration.

That distinction matters for dermatologists. Most filler data stop at neocollagenesis. Evidence that a biostimulatory agent influences multiple matrix proteins suggests a wider remodeling effect on photodamaged skin, not just volume replacement.

Why solar elastosis?

Solar elastosis is among the most common findings in aging skin, especially in fair-skinned patients with long-term sun exposure. It contributes to wrinkling, laxity and a coarse texture that resurfacing lasers and neurotoxins address only partially. An injectable that improves elastotic changes would give clinicians a tool for a compartment of aging that has few nonsurgical options.

The study's reported improvements in ECM protein levels, alongside the collagen response, point to a mechanism consistent with dermal regeneration rather than simple space-filling.

Manufacturer claims vs. trial data

Merz, which markets Radiesse, has built its positioning around the "biostimulator" label. The company's promotional materials have long asserted collagen stimulation; this study adds independent documentation of that claim and extends it to additional matrix proteins. Dermatologists should read the two separately: the approval basis for Radiesse remains soft-tissue augmentation and correction of facial wrinkles and folds, while elastosis improvement sits outside the labeled indication.

Clinicians using Radiesse off-label for broader photodamage should note that the study's endpoint was improvement in signs of solar elastosis, not regulatory approval for that use.

What comes next?

The findings, if confirmed in larger controlled cohorts, could shift how practices frame biostimulatory injectables — from volume correction toward dermal remodeling in photodamaged skin.